background

Pioneering Genetically-Targeted Cardiovascular Therapies

Annual Meeting of Stockholders of ARCA biopharma
When: Thursday, June 9, 2016, at 9:00 a.m. MDT
Where: Boulder Marriott Hotel
Address: 2660 Canyon Boulevard, Boulder, CO 80302.

ARCA biopharma’s lead product candidate, GencaroTM (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for the prevention of atrial fibrillation (“AF”) in patients with heart failure and reduced left ventricular ejection fraction (“HFREF”) in a genetically defined subpopulation.

ARCA Biopharma Menu
Menu